Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
Commercial Sponsor
Hoffmann-La Roche
Summary
Eligible patients will be randomised to receive Atezolizumab followed by Tiragolumab OR a placebo-equivalent every three weeks on Day 1 of each 21-day cycle until disease progression, lack of clinical benefit or unacceptable toxicity is observed.